Toll-like Receptors

Imiquimod (Aldara) is a a heterocyclic imidazoquinoline amide that acts as an immune response modifier.

VGX-1027 displays immunomodulatory and anti-inflammatory activities by inhibiting toll-like receptor 4 (TLR4) signaling.

MD2-IN-1 is an inhibitor of Myeloid differentiation protein 2 (MD2) with a KD of 189 ?μM for the recombinant human MD2 (rhMD2).

GS-9620 is a potent and selective orally active small molecule agonist of Toll-like receptor 7.

Hydroxychloroquine Sulfate is an antimalarial agent used for the treatment of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune, inflammatory and dermatologic conditions. Also acts as an inhibitor of autophagy and toll-like receptor (TLR) 7/9.

Resiquimod is an immune response modifier that acts as a potent TLR 7/8 agonist. Phase 2.

Gardiquimod is a chemical compound which acts selectively at both mouse and human forms of toll-like receptor 7 (TLR7). It functions as an immune response modifier. CAS: 1159840-61-5 (TFA) 1020412-43-4 (free base)

E6446 dihydrochloride is a robust antagonist for TLR7 and TLR9, with potential applications in studying harmful inflammatory responses. Additionally, it acts as a significant inhibitor of SCD1 with a KD of 4.61 μM. This compound can notably suppress adipogenic differentiation and liver lipogenesis via the SCD1-ATF3 pathway. Studies have indicated that E6446 dihydrochloride can enhance liver pathology in mice on a high-fat diet, making it a potential candidate for researching non-alcoholic fatty liver disease (NAFLD).

CU-CPT-9a is a specific TLR8 antagonist, with an IC50 of 0.5 nM.

TH1020 is a potent and selective toll-like receptor 5 (TLR5)/flagellin complex antagonist with an IC50 of 0.85 μM.